Impact of Adjuvant Chemotherapy on the Prognosis of Hormone Receptor Negative Breast Cancer with Residual Lymph Node Disease after Neoadjuvant Chemotherapy

X Wang,Y J He,J F Li,Y T Xie,T F Wang,Z Q Fan,T Ouyang
DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2017.20.015
2017-01-01
Abstract:Objective To explore the influence of adjuvant chemotherapy on the prognosis of hormone receptor negative breast cancer with residual lymph node disease(RLND)after neoadjuvant chemotherapy.Methods A total of 110 hormone receptor negative breast cancer patients treated with 4-8 cycles of neoadjuvant chemotherapy were respectively analysed between 2002 and 2012.Residual lymph node disease was comfirmed by subsequent radical mastectomy.Then all these patients were classified into two groups: patients treated with adjuvant chemotherapy(group A) and patients untreated with adjuvant chemotherapy(group B).Results All patients were female,the median age was 54.5 years old(IQR:47-59 years).The median follow-up time was 61 months(IQR:51-88 months).There were 82 patients (74.5%) in group A,and 28 patients (25.5%) in group B.The five-year disease-free survival (DFS) rate was 76.2% in group A and 57.6% in group B.The distant disease-free survival (DDFS) rate was 78.9% in group A and 60.4% in group B.Overall survival (OS) rate was 81.0% in group A and 60.0% in group B.Multivariate analysis showed that there were significant differences for DDFS rate (group A vs group B,P=0.033;hazard ratio [HR],5.256;95% confidence interval [95%CI],1.14-24.17) and OS rates (group A vs group B,P=0.011;HR,7.478;95%CI,1.58-35.30) between two groups.Conclusion The patients who have hormone receptor negative breast cancer with RLND after neoadjuvant chemotherapy,may benefit from postoperative adjuvant chemotherapy.
What problem does this paper attempt to address?